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1. Introduction
Baeyer–Villiger monooxygenases fulfil various roles in
nature
A large variety of enzymes have evolved for selective oxida-
tions in nature that include as major enzyme classes oxidases,[1]
dehydrogenases,[2] monooxygenases,[3] dioxygenases,[4] and
peroxidases.[5] Within the class of monooxygenases a subclass
of enzymes is able to catalyze Baeyer–Villiger oxidations
(Scheme 1).[6]
Baeyer–Villiger monooxygenases (BVMOs, EC 1.14.13.x) were
first isolated in the 1960s,[7] and the first BVMO-encoding
genes were identified in the 1990s.[8] The majority of all studied
BVMOs are sequence related (type I BVMOs), belong to the
subclass B flavoprotein monooxygenases,[9] carry a FAD cofac-
tor as prosthetic group, and depend on NADPH as electron
donor. All type I BVMOs described so far are of microbial
origin. Such prevalence in microbes was confirmed by analyz-
ing genome sequences. By using a BVMO-specific protein se-
quence motif, BVMOs can effectively be annotated and on
average about one BVMO gene is found in each microbial
genome.[10] However, the genomic distribution is quite special :
BVMOs are abundant in some specific microbes, for example,
actinomycetes and some filamentous fungi, whereas they are
hardly represented in other types of bacteria and appear to be
fully absent in higher eukaryotes and archaea. Along with the
observation that microbes harbor a multitude of unexplored
BVMOs, research in the past few decades has revealed that
these BVMOs are employed for a wide variety of functions by
microbes. They are involved in catabolic pathways enabling
bacteria to grow on a variety of ketones,[11] and they are also
crucial in the biosynthesis of a variety of secondary metabo-
lites.[12] Although a dedicated BVMO has evolved for each of
these metabolic steps, biocatalytic studies have also shown
that individual BVMOs can accept a formidable number of dif-
ferent substrates. For the most extensively studied BVMO, cy-
clohexanone monooxygenase from Acinetobacter calcoaceticus
NCIMB 9871 (CHMOAcineto ; EC 1.14.13.22), it has been shown
that it can convert hundreds of different compounds.[13] Except
for performing Baeyer–Villiger oxidations, this enzyme has also
been used to demonstrate the capability of BVMOs to catalyze
other oxidation reactions: for example, sulfoxidations, oxida-
tions of selenium and boron-containing compounds, epoxida-
tions, and N-oxidations. Such catalytic versatility has also been
observed for other BVMOs and is consistent with the proposed
mechanism.[14] BVMOs use a flavin cofactor for catalysis that,
after coenzyme-mediated reduction and reaction with molecu-
lar oxygen, forms a peroxyflavin intermediate. Such an enzy-
matic peracid analogue can perfectly explain the broad range
of oxidation reactions that are feasible with BVMOs. Kinetic
studies have revealed that the formation of this intermediate
does not depend on substrate binding.[15] Therefore, the reac-
tive peroxyflavin intermediate, as a cocked gun, is just waiting
for a substrate to reach the active site. The accessibility of the
active site will determine the substrate range of each BVMO.
The recently reported BVMO crystal structures have shown
that during individual catalytic steps major structural rear-
rangements occur.[16] Because no crystal structure has yet been
obtained of a BVMO in the peroxyflavin state, the exact molec-
ular basis for the substrate specificity and regio- and/or enan-
tioselectivity of BVMOs is still unclear. Nevertheless, the recent
studies have provided a wealth of information on unique cata-
lytic properties of natural or engineered BVMO, often offering
catalytic strategies that are impossible by using chemical
means. This has led to an increased interest in employing
BVMOs as synthetic tools or as (pro)drug targets. This review
provides an overview on the recent developments in BVMO-
based catalytic applications. It will focus on recently reported
biocatalytic approaches that involve BVMOs, examples of
BVMOs involved in synthesis of bioactive molecules, and
recent progress in developing effective strategies to apply
BVMOs.
Baeyer–Villiger monooxygenases (BVMOs) represent a specific
class of monooxygenases that are capable of catalyzing a vari-
ety of oxidation reactions, including Baeyer–Villiger oxidations.
The recently elucidated BVMO crystal structures have provided
a more detailed insight into the complex mechanism of these
flavin-containing enzymes. Biocatalytic studies on a number of
newly discovered BVMOs have shown that they are very
potent oxidative biocatalysts. In addition to catalyzing the
regio- and enantioselective Baeyer–Villiger oxidations of a wide
range of carbonylic compounds, epoxidations, and enantiose-
lective sulfoxidations have also been shown to be part of their
catalytic repertoire. This review provides an overview on the
recent developments in BVMO-mediated biocatalytic process-
es, identification of the catalytic role of these enzymes in meta-
bolic routes and prodrug activation, as well as the efforts in
developing effective biocatalytic methodologies to apply
BVMOs for the synthesis of high added value compounds.
Scheme 1. Baeyer–Villiger oxidation of carbonylic compounds catalyzed by
BVMOs.
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2. BVMO-Mediated Chemo- and/or Regioselec-
tive Oxidations and Desymmetrization of Pro-
chiral Substrates
CHMO and CPMO: similar and different
The biocatalytic potential of CHMOAcineto
[14,17] and cyclopenta-
none monooxygenase from Comanonas sp. NCIMB 9872
(CPMOComa; EC 1.14.13.16)
[8a,18] have been intensely studied. Be-
cause of their broad substrate tolerance and high chemo-,
regio-, and/or enantioselectivity, they are highly attractive bio-
catalysts. Comparative biocatalytic studies have recently re-
vealed that both BVMOs, although highly similar in sequence
(37% seq. identity), can be regarded as prototypes of two dis-
tinct BVMO subclasses.[19] For a number of substrates tested, it
was observed that catalysis by CHMOAcineto or CPMOComa led to
opposite regio- and/or stereoisomers as products.[20] This diver-
gence of CPMO or CHMO-like enzymes was confirmed when
using a set of BVMOs that display significant sequence identity
with one of the two prototypes. Thus, two enzymatic clusters
were established for these enzymes. The CHMO-type group is





[21b,c, 22] and Brevibacterium HCU
(CHMOBrevi1),
[23] whereas the CPMO-type family consists of
CPMOComa and another BVMO from Brevibacterium
(CHMOBrevi2).
[24] Recently, Escherichia coli expressing the two
prototype biocatalysts, CHMOAcineto and CPMOComa, were used
for the oxidation of a set of 4-substituted 3,5-dimethylcyclo-
hexanones (Scheme 2 and Table 1).[25] All tested ketones were
converted into the corresponding lactones with good yields
and high optical purities when employing CHMOAcineto. Only
the oxidation of 3,5-dimethyl-4-methylenecyclohexanone was
performed with a slightly decreased enantioselectivity. In con-
trast, CPMOComa was only able to oxidize this latter compound
and 3,5-dimethylcyclohexanone. For both compounds, excel-
lent enantioselectivities were obtained in the formation of the
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Scheme 2. BVMO-catalyzed oxidation of 4-substituted-3,5-dimethylcyclohex-
anones employing CHMOAcineto and CPMOComa.
[25]
Table 1. Biotransformation of 4-substituted-3,5-dimethylcyclohexanones
catalyzed by CHMOAcineto and CPMOComa-expressing recombinant cells.
[25]
R Enzyme Yield [%][a] ee [%][b] [a]20D
cis-OH CHMO 77 99 24.5 (1.71, CHCl3)
cis-OH CPMO n.c.[c] n.a.[d] n.a.[d]
trans-OH CHMO 80 96 +53.7 (1.76, CHCl3)
trans-OH CPMO n.c.[c] n.a.[d] n.a.[d]
=CH2 CHMO 54 92 +8.4 (0.80, CHCl3)
=CH2 CPMO 63 99 8.6 (1.00, CHCl3)
H CHMO 65 99 12.7 (2.00, CHCl3)
H CPMO 58 91 +7.7 (1.30, CHCl3)
[a] Yield after purification by column chromatography. [b] Determined by
GC. [c] No conversion. [d] Not applicable.
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lactones, which again were found to be antipodal to the ones
obtained with CHMOAcineto. The oxidation of the cis-4-hydroxy-
3,5-dimethylcyclohexanone led to the corresponding lactone,
which suffers a rearrangement process leading to a chiral bu-
tyrolactone that is a key intermediate in the synthesis of caly-
culin and tirandamycin A.
A set of bridged cycloketones has also been synthesized and
employed as substrates by using CHMO and CPMO-type
BVMOs.[26] Interestingly, four to six stereogenic centers can be
created by desymmetrization of these ketones. For almost all
the ketones tested, again, enantiodivergent behavior of both
BVMO subclasses was observed. Thus, CHMO-type BVMOs led
to the (+)-lactones, whereas oxidations catalyzed by CPMOComa
and CHMOBrevi2 afforded the ()-lactones.
The biocatalyzed Baeyer–Villiger oxidation of 4,4-disubstitut-
ed cyclohexanones, that had been previously performed by
using CHMOAcineto,
[27] has recently been tested with a larger set
of CHMO- and CPMO-type BVMOs.[28] Most of the BVMOs em-
ployed were found to effectively convert 4,4-dimethylcyclohex-
anone, with the exception of CHMOBrevi1, which showed low re-
activity for all these substrates. Biotransformation of 4-ethyl-4-
methylcyclohexanone led to the corresponding lactone with
good yields and enantiomeric excesses around 80% for the
CHMO-family, whereas the CPMO-type enzymes displayed
much lower selectivity while yielding the same enantiomer of
the lactone. Biooxidation of 4-hydroxy-4-methylcyclohexanone
resulted in the enantiodivergent formation of both lactones
depending on the employed CHMO or CPMO-type enzyme.
With the CHMO-type enzymes the synthesis of the ()-lactone
was possible, whereas, with only moderate enantiomeric ex-
cesses, the (+)-lactones were obtained when using a CPMO-
type BVMO. The final 7-membered ring product undergoes a
spontaneous rearrangement to afford the more stable 5-mem-
bered ring lactone. Recently, the CHMO from Xanthobacter sp.
XL5, cloned in 2003 and classified as a CHMO-type BVMO,[22]
has been employed for the oxidation of 4,4-disubstituted cy-
clohexanones, leading to the corresponding ()-lactones with
good yields and high enantiomeric excesses.[29] This enzyme
was able to catalyze the oxidation of 4-methyl-4-phenylcyclo-
hexanone, which was not a substrate for the rest of the re-
combinant BVMOs tested.
Both BVMO-subclasses have also been employed for the en-
zymatic Baeyer–Villiger oxidation of a set of prochiral alkyl di-
substituted perhydropyran-4-ones.[30] Previous experiments had
established that the oxidation of perhydropyran-4-one oc-
curred with high yields for all the enzymes tested.[31] The pres-
ence of different alkyl chains led to a remarkable difference in
substrate acceptance: CHMO-type enzymes displayed a high
efficiency and selectivity in the oxidation of alkyl chains up to
three linear carbon atoms to obtain the final (2S,7R)-lactones,
whereas the presence of more branched substituents or longer
chains was not accepted by CHMOs. The CPMO-group was not
able to convert all of these substrates. However, CPMOs were
found to oxidize constrained bicycloperhydropyran-4-ones
leading to the corresponding (1S,6S)-lactones with moderate
yields and high enantiomeric excess. Such conversion was not
observed for the CHMO-type enzymes.
Exploring chemoselectivity of BVMOs
Although it has been shown that CHMOAcineto can be used to
perform Baeyer–Villiger oxidation with a variety of ketones, in
particular by focussing on achieving good regio- and/or enan-
tioselectivity, little attention has been paid to explore possible
chemoselectivity. Only a few studies on substrates presenting
more than one group susceptible to enzymatic oxidation have
been conducted. It has been shown some years ago, that oxy-
genation proceeds preferably at the carbonyl group in the
presence of other oxidizable functional groups (alkenes, thio-
ethers).[30–32] Recently, the chemoenzymatic Baeyer–Villiger oxi-
dation of bicyclic diketones catalyzed by a crude preparation
of CHMOAcineto expressed in E. coli has been employed to syn-
thesize different ketolactones, compounds that are of interest
as key intermediates in natural products.[33]
The CHMO-catalyzed oxidation of the Wieland–Miescher
ketone (1) was completely selective to generate the corre-
sponding enantiopure (S)-ketolactone, (S)-2 from the saturated
carbonyl group, whereas the unreacted (R)-diketone was recov-
ered in 43% yield and 80% enantiomeric excess (Scheme 3).
Racemic 8a-methylhexahydronaphthalene-1,6-dione ( )-3 was
chemoselectively oxidized to give the (5aR,9aS)-ketolactone 4
with excellent enantiomeric excess. Formation of 32% of enan-
tiopure ketoalcohol 5 was observed due to the presence of a
dehydrogenase in the BVMO preparation. Chemical epoxida-
tion of the racemic Wieland–Miescher ketone led to an epoxi-
dione 6, which is transformed by CHMO catalysis into the
enantiopure lactone (1R,3S,7S)-7 as the only Baeyer–Villiger
product. This conversion also afforded 32% of the unaltered
starting (1aR,4aR,8aR)-epoxidione with 95% optical purity and
an 11% of enantiopure ketoalcohol 8 generated again by a de-
hydrogenase activity on the starting material.
Scheme 3. CHMOAcineto-catalyzed chemoselective oxidation of bicyclic ke-
tones.[33] a) Tris-HCl, 50 mm, CHMOAcineto, G6P/G6PDH.
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BVMOs govern regioselectivity
The regioselectivity of the Baeyer–Villiger oxidation is gov-
erned by steric, conformational and electronic effects typically
leading to migration of the more-substituted (the more nucle-
ophilic) carbon center for chemical oxidations. Such migratory
aptitude is also seen in the majority of the enzyme-catalyzed
Baeyer–Villiger oxidations. In some cases, however, the use of
BVMOs has led to the formation of the “unexpected” or “ab-
normal” lactones. This underscores the unique properties of
BVMO that can be of use in synthetic chemistry. It is suggested
that in these cases the chiral environment of BVMOs imposes
restrictions that determines which moiety will migrate, as cer-
tain stereoelectronic requirements have to be met in order to
allow for the rearrangement process. As a result, in several
cases BVMOs have been shown to afford one of the regioiso-
merically possible lactones that might be different from the
“expected” or “normal” lactone. In the last few years, several
atypical regioselective Baeyer–Villiger oxidations have been de-
scribed by using BVMOs as catalysts.
The collection of CHMO and CPMO-type BVMOs expressed
in recombinant E. coli strains has been applied for the regiodi-
vergent biooxidation of different terpenones.[34] Baeyer–Villiger
reaction of ()-trans-dihydrocarvone (9) and ()-carvomen-
thone (10) catalyzed by CHMO-type enzymes led to the forma-
tion of the expected lactones (11 and 12, respectively) with
good to excellent conversions. However, the opposite enantio-
mers (+)-trans-dihydrocarvone and (+)-carvomenthone were
transformed into the (+)-unexpected lactones, whereas the
use of CPMO-type biocatalysts led in all cases to the exclusive
formation of the unexpected compounds (13 and 14), albeit
with low conversions (Scheme 4). ()-cis-Dihydrocarvone was
converted to the expected lactone in high yields by CHMO-
type BVMOs, whereas the CPMO enzymes afforded the unex-
pected products. The (+)-cis enantiomer was converted with
low regioselectivities by all the BVMOs tested.
CHMO and CPMO-type enzymes have also been employed
for the biooxidation of a set of fused cyclobutanones.[35] This
again revealed divergent catalytic behavior: the CHMO-type
enzymes are able to oxidize these compounds to form both
possible regioisomeric lactones with high optical purities,
whereas the CPMO-type BVMOs led to the formation of the ex-
pected lactones as the only regioisomer. Thus, the two BVMOs
subclasses can nicely complement each other for covering a
broad range of reactions. Remarkably, a recently characterized
BVMO from Mycobacterium tuberculosis displayed preferred for-
mation of the atypical lactone in a kinetic-resolution process.[36]
E. coli cells expressing 4-hydroxyacetophenone monooxyge-
nase (HAPMO; EC 1.14.13.81)[37] from Pseudomonas fluorescens
ACB have also been employed in the regiodivergent oxidation
of several bicycloketones.[38] The biotransformation of bicyclo-
[3.2.0]hept-2-en-6-one led mainly to the unexpected lactone in
low enantiomeric excess, whereas the expected lactone was
achieved with 75% ee. A similar trend was observed for the de-
rivatives presenting a five-membered ring, for which the for-
mation of the unexpected lactone with low enantiomeric ex-
cesses was favored, whereas the normal lactones presented
much higher optical purities. In contrast, when oxidizing bicy-
cloketones containing a six-membered ring, the major product
was the normal lactone. In this case, the highest enantiomeric
excesses were measured for the unfavored abnormal lactones.
These examples again demonstrate the ability of BVMOs to
tune regio- and/or enantioselectivity.
HAPMO has been also used in the regioselective transforma-
tion of fluorobenzaldehydes to fluorophenols,[39] compounds
with applications as pharmaceuticals, agrochemicals and mate-
rials. The Baeyer–Villiger oxidation of the starting aldehydes
leads to the corresponding esters, which are hydrolyzed to flu-
orophenols as main products, whereas only about 5% of fluo-
robenzoic acid (the other regioisomeric product) was observed.
The use of the biocatalyst allows synthesis of the regioisomer
(phenol ester) that is opposite to the one that is achieved by
conventional chemical methods (benzoic acid); hence, this
transformation can be considered as the biological equivalent
to the Dakin reaction. The atypical outcome of this enzymatic
oxidation is probably due to specific interactions of the benzal-
dehyde substrate with amino acids and flavin cofactor in the
active site of HAPMO that favor the migration of the phenyl
group.
BVMO as biocatalysts for the synthesis of b-amino acids
b-Amino acids are of considerable industrial interest due to
their application as building blocks for the preparation of b-
peptides, alkaloids, terpenoids, and b-lactam antiobiotics. Re-
cently, a set of BVMOs from different bacterial origin have
been employed as biocatalysts in the oxidation of linear ali-
phatic ketones possessing an amino group in the b position.[40]
Whereas no reaction was observed for all the BVMOs tested
when the amino group was unprotected, four of these en-
zymes [cyclodecanone monooxygenase (CDMO;
EC 1.14.13.x)[41] from Rhodococcus ruber SC1, CHMOArthro,
CHMOBrachy, and CHMOXantho were active on ( )-methyl (2-
methyl-6-oxooctan-4-yl)carbamate 15, leading to the formation
of both possible regioisomeric lactones with excellent enantio-
selectivities. CDMO oxidizes the (+)-enantiomer of the starting
ketones, generating the (+)-lactones, whereas the rest of the
Scheme 4. Regiodivergent oxidation of ()-trans-dihydrocarvone and ()-
carvomenthone by employing different BVMOs.[34]
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BVMOs generate the ()-enantiomer. After isolation and purifi-
cation of both protected b-amino esters (16 and 17) and hy-
drolysis by Candida antarctica lipase B, N-protected-b-leucine
(18) and N-protected b-amino-4-methyl-1-pentanol 19 (a-leu-
cine precursor) was obtained (Scheme 5). Whereas only a re-
stricted set of BVMOs and b-amino acid precursors have been
explored, it is likely that with other BVMO types a much broad-
er range of b-amino acids can be prepared by this novel
BVMO-based process. This conceptionally new biocatalytic
route to b-amino acids nicely illustrates the biocatalytic poten-
tial of BVMOs. The study has been recently extended by em-
ploying a collection of 16 BVMOs in the Baeyer–Villiger oxida-
tion of different 4-amino-2-ketones and 5-amino-3-ketones,[42]
being found excellent selectivities (E200)[43] in the resolution
of aromatic and aliphatic 4-amino-2-ketones. The intermediate
b-amino alkyl acetates underwent autohydrolysis, yielding the
optically pure b-amino alcohols.
3. Kinetic and Dynamic Kinetic Resolutions
Applied to BVMO-Catalyzed Processes
Kinetic resolutions of racemic ketones catalyzed by BVMOs
The resolution of racemic mixtures is nowadays a popular and
important industrial approach for the synthesis of compounds
in an optically active form. Whereas quite some examples have
been described in which BVMOs were employed for the de-
symmetrization of prochiral compounds, the kinetic resolution
of racemic ketones in order to obtain enantiopure ketones,
esters or lactones had not been intensely studied until recently.
Only some experiments have been developed in the kinetic
resolution of substituted cycloalkanones.[18b,44] In the last few
years several studies have appeared that demonstrate the use
of BVMOs in kinetic resolutions. Recently, a set of cyanocyclo-
hexanones have been oxidized by whole cells of E. coli express-
ing CHMOAcineto.
[45] Ketones possessing a cyano group in their
structure are highly interesting in organic synthesis because
the nitrile moiety can be transformed into several other
groups, like amides, acids, or amines, providing access to a
wide set of interesting compounds. Under the employed con-
ditions, the nitrile group did not undergo any reaction, con-
firming the absence of nitrile hydratases or nitrilases in the em-
ployed E. coli hosts. The study showed that when the cyano
group was directly attached to cyclohexanone, no reaction
was observed (as expected for an enolyzable carbonyl group).
However, excellent results were obtained with the cyanoethyl
derivative because it gave a highly enantioselective conversion
(E200). The conversion yielded the normal caprolactone of
the R configuration, whereas it was also possible to recover
the S-ketone. In contrast, the biooxidation of 2-cyanomethylcy-
clohexanone ( )-20 led to a regiodivergent parallel kinetic res-
olution in which both regioisomeric lactones are formed,[46]
each one arising from one of the two enantiomers of the start-
ing ketone, as shown in Scheme 6. The formation of the ex-
pected (R)-lactone 21 is slightly faster than the unexpected
one with the S configuration, 22, but both products could be
recovered as enantiopure compounds (ees 99%).
E. coli cells expressing cyclopentadecanone monooxygenase
from Pseudomonas sp. (CPDMO) have also recently been used
in kinetic-resolution processes. The resolution of racemic 2-
methylcyclopentadecanone occurs with low conversion and a
very poor enantioselectivity, yielding the final (S)-lactone in
65% ee. Much better results were shown by this enzyme when
oxidizing ( )-2-methylcyclohexanone. An excellent E value was
achieved in the formation of enantiopure (S)-2-methylcaprolac-
tone with 46% conversion. This enzyme led to low or moder-
ate enantioselectivities when resolving substituted racemic cy-
clopentanones.[47]
Scheme 5. Enzymatic synthesis of b-amino-4-methyl-1-pentanol and N-protected-b-leucine by combining a BVMO-catalyzed oxidation with subsequent hy-
drolysis catalyzed by Candida antarctica lipase B. a) E. coli whole cells, BVMO; b) CAL-B, 50 mm phosphate, pH 7.5.[40]
Scheme 6. Regiodivergent parallel kinetic resolution of 2-cyanomethylcyclo-
hexanone catalyzed by whole cells of CHMO from Acinetobacter calcoaceti-
cus.[45] a) E. coli cells, CHMOAcineto.
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A BVMO from M. tuberculosis H37Rv has been expressed in
E. coli and employed as biocatalyst in the kinetic resolution of
fused bicyclic ketones (Scheme 7).[36] Interestingly, almost com-
plete conversions were observed after 48 h, affording the un-
expected lactones with around 70% regioisomeric excess. Low
enantiomeric ratios were measured for all the substrates. This
enzyme was also used as biocatalyst in the selective oxidation
of heterobicyclic fused ketones containing oxygen, yielding
low or moderate enantioselectivities with the exception of rac-
emic 2-oxabicyclo[4.2.0]octan-7-one 23, which was oxidized
with complete regioselectivity to the unexpected lactone 3-
oxabicyclo[3.3.0]octan-2-one. Both (1S,6R)-()-lactone 24 and
(1R,6S)-(+)-ketone 23 were obtained in enantiopure form after
50% conversion. This biotransformation is of high interest be-
cause the chiral starting ketone is a key intermediate in the
synthesis of prostanoid synthons, and the lactones are interest-
ing precursors for the synthesis of natural compounds present-
ing a tetrahydropyran core.
Whole cells of recombinant E. coli expressing the recently
discovered BVMO from Pseudomonas fluorescens DSM 50106
were employed for the first time in the kinetic resolution of
racemic aliphatic ketones. This biocatalyst has been previously
identified as a BVMO with high specificity for aliphatic ke-
tones.[48] It can be used to obtain octyl acetate, heptyl propio-
nate, and hexyl butyrate and even longer alkyl chain esters.
For a kinetic resolution, this BVMO was employed in the selec-
tive oxidation of a set of racemic 4-hydroxy-2-ketones, afford-
ing the (S)-hydroxyalkyl acetates with good enantioselectivities
(E values around 50).[49] An acetyl migration of the final esters
from the primary to the secondary hydroxy group was ob-
served, yielding a 4:1 mixture of the monoacetylated 1,2-diols.
Only small amounts of the other possible Baeyer–Villiger oxida-
tion products were observed (<5%). Kinetic resolution of race-
mic hydroxyketones was then extended by employing a large
set of substrates and by analyzing eleven additional BVMOs of
various bacterial origin.[50] All of the tested enzymes oxidized
the S enantiomer of the starting material, yielding the (R)-hy-
droxyketones. In general, short and middle-chain ketones were
preferred with a loss in enantioselectivity when increasing the
alkyl chain of the starting ketones. Protection of the hydroxyl
group before the biocatalyzed oxidation led to lower substrate
acceptance of the CHMO-type enzymes. Again, the formed (S)-
hydroxyalkyl esters undergo acyl migration to form the corre-
sponding acetates of 1,2-diols in optically active form. Further-
more, the location of the carbonyl group in the substrate can
influence the regioselectivity of the oxidation. Although
methyl esters as atypical oxidation products were formed in
low yields for 4-hydroxy-2-ketones (less than 10%), the use of
5-hydroxy-3-ketones led to more pronounced formation of the
unexpected oxidation product.
Racemic benzylketones have also recently been tested as
substrates of BVMOs in kinetic-resolution processes. Thus,
E. coli cells expressing the BVMO from P. fluorescens DSM 50106
as well as CHMOAcineto, CPMOComa and a BVMO from Pseudomo-
nas putida KT2440[51] were used as oxidative biocatalysts in the
resolution of racemic ( )-3-phenylbutan-2-one and ( )-3-phe-
nylpentan-2-one to obtain the corresponding (S)-esters and
(R)-ketones.[52] With exception of the kinetic resolution cata-
lyzed by CPMOComa, which occurred with high stereoselectivity,
low to moderate E values were achieved. Much better results
were obtained when employing the isolated BVMOs phenyl-
acetone monooxygenase (PAMO; EC 1.14.13.92) from Thermo-
bifida fusca and HAPMO.[53] These two enzymes, primarily
active on aromatic substrates, were able to oxidize a set of
short-alkyl-chain benzylketones with excellent enantioselectivi-
ties providing access to (S)-benzylesters and remaining (R)-ben-
zylketones. For all the compounds tested, reactions were much
faster and selective when employing PAMO. Some of the reac-
tion parameters that can affect the biocatalytic properties
were studied in the resolution of ( )-3-phenylpentan-2-one.
This revealed that a higher pH (pH 9.5) resulted in higher pro-
ductivity.[54] Concerning the temperature, it was shown that
40 8C was the optimum temperature for PAMO (this enzyme is
even able to catalyze oxidations at 60 8C), whereas the maxi-
mum performance for HAPMO was found at 20 8C. Finally, sub-
strate concentrations higher than 10 gL1 inactivated HAPMO,
whereas PAMO is not affected to such an extent by the
amount of substrate. This confirms the robustness of PAMO as
biocatalyst, being derived from a thermophilic bacterium.[55]
This study was further extended to other benzylketones, in-
cluding the recently cloned and overexpressed M446G mutant
of PAMO (Scheme 8 and Table 2).[56] 3-Phenylbutan-2-ones with
different substituents in the aromatic moiety were resolved by
a selective oxidation processes, leading in all cases to the (S)-
esters and the (R)-ketones. PAMO shows higher reactivity than
its mutant and HAPMO, and the highest conversions were ob-
tained for ketones bearing electron-withdrawing groups in the
aromatic ring (3-trifluoromethyl and 4-nitro). The BVMO-cata-
lyzed oxidation of long-alkyl-chain benzylketones was found to
be a process with low conversion and poor E values. Only the
M446G PAMO-catalyzed oxidation of ( )-4-phenylheptan-3-
one and the HAPMO-based kinetic resolution of ( )-4-phenyl-
hept-6-en-3-one progress with high enantioselectivities, albeit
Scheme 7. Kinetic resolution of fused bicyclic ketones catalyzed by whole
cells of E. coli expressing a BVMO from Mycobacterium tuberculosis H37Rv.[46]
a) BVMO.
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with low conversions. The results shown that by proper selec-
tion of a BVMO, moderate to good E values can be achieved
for kinetic resolution of aromatic ketones.[57]
BVMOs in dynamic kinetic resolution processes
The main drawback kinetic-resolutions processes present is
that the theoretical yield for both substrate and product is lim-
ited to 50%. Strategies to increase the yield are therefore of
great importance. By combining an in situ racemization of sub-
strate with an enzymatic resolution, a dynamic kinetic resolu-
tion (DKR) can be achieved. This allows the transformation of
both enantiomers of the starting material into a single enantio-
meric product in 100% theoretical yield. For obtaining an effi-
cient DKR process, certain requirements must be fulfilled, such
as the irreversibility of the kinetic resolution, the absence of
product racemization and the need for good enantioselectivity
in the catalyzed resolution step. Numerous successful exam-
ples of DKR methods have been described recently.[58] Some of
them involve only conventional chemical methods, but in
others chemical and biocatalytic processes are combined. In
the latter case, the biocatalyst can act as racemization agent or
contribute to the kinetic resolution. Reports on BVMO-based
DKRs are scarce but a few examples were recently reported.
The Alphand/Furstoss group has described the first example
of dynamic kinetic resolution catalyzed by BVMOs.[59] E. coli
cells expressing CHMOAcineto were employed in the selective ox-
idation of racemic 2-benzyloxymethylcyclopentanone. This
substrate, bearing an acidic hydrogen in position a to the car-
bonyl moiety, spontaneously racemizes via keto–enol tautome-
rization leading to (R)-6-benzyloxymethyltetrahydropyran-2-
one with 75% yield and 98% enantiomeric excess. However,
this methodology suffered from certain important disadvantag-
es: 1) the need for working at high pH, at which a loss in enzy-
matic activity for particular biocatalysts is observed; 2) the sub-
strate concentration had to be low and 3) the protocol is only
applicable to acidified a-centers. An improved DKR process
has been developed by combining the whole-cell-catalyzed
Baeyer–Villiger oxidation with an in situ racemization, catalyzed
by a weak anion-exchange resin. Thus, enzymatic oxidations
can be performed at neutral pH, optimal for CHMOAcineto activi-
ty, and substrate concentration can be relatively high. With this
method, (R)-6-benzyloxymethyltetrahydropyran-2-one can be
obtained in 84% yield and 97% enantiomeric excess.[60] Re-
cently, the preparation of a set of optically active benzylesters
with high conversions and enantiomeric excesses has been de-
scribed by performing the DKR of racemic benzylketones em-
ploying isolated HAPMO.[61] The initial studies were performed
with ( )-3-phenylbutan-2-one. This ketone maintains its opti-
cal purity at relatively high pH, whereas it readily racemizes in
the presence of anion-exchange resins. Thus, the oxidation of
the substrate was carried out in the presence of different
anion-exchange resins. Resins displaying a strong character
(quaternary ammonium functional group) led to a fast sub-
strate racemization, but also were found to inactivate the bio-
catalyst. Worse racemization but much better biocatalytic re-
sults were obtained with weak resins with a tertiary amine
functional group. (S)-Phenylethyl acetate could be obtained
with 84% enantiomeric excess and 86% conversion in the op-
timal reaction conditions. This methodology was extended to
the preparation of other (S)-benzylesters with moderate to
good conversions and enantiomeric excesses depending on
the substrate structure, as indicated in Scheme 9.
4. Use of Baeyer–Villiger Monooxygenases for
Other Oxidative Processes
BVMO-catalyzed sulfoxidation reactions
As mentioned above, BVMOs catalyze not only the Baeyer–Vil-
liger reaction, but also various other oxidation reactions.
Scheme 8. Isolated BVMO-catalyzed kinetic resolution of rac-benzylketones
to obtain optically active (R)-benzylketones and (S)-benzylesters. a) Tris-HCl
50 mm, BVMO, G6P/G6PDH.
Table 2. Preparation of chiral benzylketones and benzylesters by kinetic
resolution catalyzed by isolated BVMOs.
R1 R2 X BVMO t [h] c [%]
[a] E[b]
Me Me H PAMO[c] 1 27 188
Me Me 3-Me HAPMO[d] 2 20 126
Me Me 3-CF3 HAPMO
[d] 2 39 112
Me Me 4-NO2 M446G
[d] 1 50 121
Me Et H PAMO[c] 1 19 >200
Et Me H PAMO[c] 1 32 >200
Pr Et H HAPMO[d] 4 23 66
Allyl Et H HAPMO[d] 4 5 104
[a] Determined by GC or HPLC. [b] See ref. [43] . [c] See ref. [55] . [d] See
ref. [57] .
Scheme 9. DKR of racemic benzylketones by combining the HAPMO-cata-
lyzed Baeyer–Villiger oxidation and racemization by an anion-exchange
resin.[61] a) HAPMO/Tris-HCl, pH 10, G6P/G6PDH/NADPH, 25 8C/250 rpm;
b) Dowex MWA1.
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Whereas all BVMOs discovered so far are merely meant to cata-
lyze a Baeyer–Villiger reaction in nature, their ability to catalyze
for example, enantioselective sulfoxidations makes them highly
attractive for synthetic applications. The BVMO-catalyzed oxi-
dation of prochiral sulfides is an interesting process that leads
to the formation of chiral sulfoxides,[62] compounds intensely
employed in organic chemistry as auxiliaries in asymmetric
synthesis and chiral ligands in enantioselective catalysis. Chiral
sulfoxides have also been used as key intermediates in the
preparation of biologically activity compounds or possess this
activity by themselves. The oxidation of organic sulfides was
first studied by the Walsh group by using CHMOAcineto as a bio-
catalyst,[63] and afterwards this enzyme has been employed in
the preparation of a wide set of chiral sulfoxides, usually with
high selectivities.[32,64] Purified PAMO has been recently em-
ployed as a chiral catalyst for the synthesis of various chiral ar-
omatic sulfoxides. This enzyme was able to catalyze the enzy-
matic sulfoxidation of alkyl phenyl sulfides with moderate
enantioselectivity. Better results were achieved in the sulfoxida-
tion of alkyl benzyl sulfides, especially for those possessing a
methyl or ethyl alkyl chain (ees 94%).[65] For some of the sulf-
oxides, a change in their optical purity was observed as a func-
tion of time, indicating that this BVMO was also able to cata-
lyze the enantioselective kinetic resolution of racemic sulfox-
ides, oxidizing preferably one enantiomer of the racemic mix-
ture to the achiral sulfone. High E values were obtained for
benzyl methyl and benzyl ethyl sulfoxides, indicating that the
higher optical purities achieved by conversion of the corre-
sponding sulfides are due to the asymmetric oxidation of the
sulfide combined with the kinetic resolution of the formed
sulfoxide to the sulfone. Purified HAPMO has also been used in
the preparation of chiral aromatic sulfoxides, presenting a dif-
ferent behavior to that observed for PAMO.[66] This enzyme
showed a high preference for the oxidation of alkyl phenyl sul-
fides, yielding the (S)-alkyl phenyl sulfoxides with good to ex-
cellent enantiomeric excesses. HAPMO was also shown to be
able to perform enantioselective sulfoxidations of bulky aro-
matic sulfides: for example, it oxidizes methyl 2-naphtyl sulfide
with a high selectivity (ee=95%).
Chiral b-hydroxysulfoxides are of special interest as chiral
auxiliaries and as building blocks for the synthesis of com-
pounds such as benzoxathiepines, allylic alcohols, or macro-
lides. Recently, a biocatalyzed procedure for the synthesis of
these compounds has been described by oxidizing the corre-
sponding b-hydroxysulfides by using isolated CHMOAcineto.
[67]
Sulfoxidation of trans-2-(phenylsulfinyl)cyclohexan-1-ol oc-
curred with excellent regio- and enantioselectivity for the prep-
aration of the (1S,2S)-b-hydroxysulfoxide.
Other BVMO-catalyzed oxidations
It has been described that BVMOs are able to perform a set of
alternative oxidation reactions, such as the biotransformation
of selenides to selenoxides,[68] boronic acids to phenols,[68] terti-
ary amines to N-oxides[69] and even the epoxidation of double
bonds to the corresponding epoxides.[70]
CHMOAcineto has been recently employed in the oxidation of
secondary amines under mild reaction conditions, yielding the
corresponding nitrones as the final products.[71] These com-
pounds are highly versatile synthetic intermediates, especially
as 1,3-dipoles, and they possess pharmacological activity. The
BVMO-catalyzed oxidation occurred through a double oxida-
tion, starting with oxidizing the amine followed by oxidation
of the hydroxylamine intermediate which led to two regioiso-
meric nitrones. As expected, the use of bulkier secondary
amines led to lower conversions. The M446G PAMO mutant
has also been able to convert indole (25), a secondary amine,
into indigo blue (26) during cultivation (Scheme 10A).[56]
Whereas the exact mechanism of this oxidation reaction is ob-
scure, it is thought to be initiated by N-oxidation of the endog-
enous indole generated from tryptophan by tryptophanase in
E. coli. This is in line with the fact that the enzyme is also able
to oxidize for example, N-methylbenzylamine. The conversion
of indole into indigo blue could also be performed by using
isolated enzyme. Whereas this was the first study in which a
BVMO was shown to be able to produce indigo blue, recently
other BVMOs were identified from a metagenomic library that
are also able to convert indole into indigo blue.[72]
Another documented activity of BVMOs is the oxidation of
boron-containing compounds. In a recent study it has been
shown that such reaction is also feasible with PAMO and
HAPMO because they are able to oxidize phenylboronic acid
(27) into phenol (Scheme 10B).[65,66] For a long time the epoxi-
dation of vinyl-phosphonates by CHMOAcineto was the only de-
scribed BVMO-mediated epoxidation.[70] Interestingly, recently
it was discovered that the oxidation of the bicyclic ketone 7-
oxabicyclo[2.2.1]hept-5-en-2-one (28) by whole cells of the
BVMO from Xanthobacter sp. did not lead to the Baeyer–Villig-
er oxidation product. Instead, formation of the epoxide 29
Scheme 10. Alternative oxidation reactions performed by BVMOs. A) M446G
PAMO biooxidation of indole to indigo blue,[56] B) Biocatalyzed oxidation of
phenylboronic acid to phenol,[65, 66] and C) Epoxidation of 7-oxabicyclo-
[2.2.1]hept-5-en-2-one catalyzed by CHMOXantho.
[29] a) E. coli cells, M446G
PAMO; b) PAMO or HAPMO; c) CHMOXantho.
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from oxidation of the double bond was observed. This excep-
tional behavior for a BVMO can be rationalized by the elec-
tron-rich character of the double bond in combination with a
particular secondary interaction by the oxygen bridge, which
can lead to an electrophilic oxygenation to form the corre-
sponding epoxide (Scheme 10C).[29]
5. Special Modes of Applying Baeyer–Villiger
Monooxygenases
BVMO-catalyzed oxidations in presence of organic
cosolvents
In nature, biocatalysts typically act in an aqueous medium.
However, it has been established since more than 20 years
that enzymes can also be active in reaction media containing
organic solvents.[73] Biocatalytic reactions in organic media
present some advantages compared to the use of aqueous sol-
utions, for example, 1) higher solubility of hydrophobic sub-
strates, 2) enabling reactions not accessible in water, 3) preven-
tion of unwanted side reactions, 4) facilitating recovery and re-
cycling of enzymes, and 5) solvents have been shown to im-
prove chemo-, regio- and/or enantioselectivity. Unfortunately,
the use of organic solvents also often causes drawbacks, such
as the lower enzymatic activity or the limitation of mass trans-
fer in the case of biphasic systems. Hydrolytic enzymes have
been widely used in organic reaction media, whereas only rela-
tively few examples in which oxidoreductases were employed
in nonaqueous systems have been described.[74]
In the last few years several studies have focused on the use
of BVMOs in the presence of organic solvents. It has been
found that the Baeyer–Villiger oxidation of benzofused ketones
proceeded with higher conversions by employing different or-
ganic cosolvents in a 5% (v/v) concentration in the reactions
catalyzed by isolated PAMO, its M446G mutant, and HAPMO.[75]
Tetralones were bad substrates for the three enzymes in buffer.
However, the addition of 5% of hydrophobic solvents, such as
toluene or 2-octanol, allowed to convert 1-tetralone into 4,5-di-
hydro-1-benzoxepin-2(3H)-one. This clearly demonstrates the
benefits of applying organic (co)solvents for biocatalysis. When
conversion of 2-indanone was studied, addition of 5% of co-
solvents was found to improve the conversion, leading to a
90% conversion when using 1,4-dioxane. Considering oxida-
tion of 1-indanone and derivatives substituted in the aromatic
moiety, also better conversions could be achieved by adding
organic solvents. HAPMO leads to the formation of the “ex-
pected” lactones with improved conversions when adding hy-
drophobic solvents (hexane, toluene, or octan-2-ol), whereas
M446G PAMO is able to form the “unexpected” lactone with
the best results in 5% of hydrophilic solvents (methanol, 1,4-
dioxane, or isopropanol). Thus, by selecting the biocatalyst and
reaction media properly, both regioisomeric lactones could be
obtained from a set of 1-indanones with excellent yields, as in-
dicated in Scheme 11. It was also shown that HAPMO is still
active in mixtures with 50% hexane whereas M446G PAMO
can tolerate 30% methanol.
The use of biphasic reaction media can also serve to stabilize
BVMOs under reaction conditions with high concentrations of
substrate. A recently engineered PAMO mutant “P3”[76] suffered
a drastic deactivation when the substrate concentration was
increased to more than 1 gL1in the whole-cell oxidation of
different ketones. To overcome this inhibition, a second organ-
ic phase was employed as a substrate reservoir and product
sink, resulting in full conversions in a mixture of buffer/dioctyl-
phthalate 1:1 at ketone levels of 3 gL1. Reactions were also
carried out by employing the purified enzyme coupled to the
alcohol dehydrogenase from Thermoanaerobacter ethanolicus
as a cofactor regeneration system. The presence of detergents
such as Tween 20 had a positive effect on PAMO mutant stabil-
ity when working in biphasic media with 50% organic cosol-
vents. The use of cyclohexane and tert-butyl methyl ether had
only a moderate influence on the biocatalyst, whereas other
cosolvents led to a fast enzymatic deactivation. Thus, a 200 mL
biotransformation of 5 gL1 of 4-phenylcyclohexanone using
tert-butyl methyl ether and aqueous buffer as reaction
medium catalyzed by PAMO-P3 has been described.[77]
Recombinant E. coli whole cells containing CPDMO have also
been used in the oxidation of cyclododecanone to lauryl lac-
tone. This was done out in a two-phase partitioning bioreactor
(TPPB), consisting of an organic and an aqueous phase that
contains the biocatalyst and the growth media. The biotrans-
formation performed in a batch process by using hexadecane/
water as reaction media led to a maximum lauryl lactone pro-
duction of 2.4 gL1 after 10 h. These results were improved by
using a variation of the TPPB system, the two-phase semicon-
tinuous reactor (TPSCR, Figure 1) in which the cells are grown
in the aqueous phase by feeding nutrients.[78] The organic
phase serves as a carrier of the reactant and an extraction
medium for the in situ removal of product. Mixing and aera-
tion of the system were interrupted for 20 min to allow the
separation of the layers, which discharged part of the aqueous
phase containing aged cells, metabolites, and debris of dying
cells while the organic phase was maintained. When the used
cells are periodically discharged (ten times) over a period of
132 h, a plateau in lauryl lactone (99 mm) was observed after
72 h, demonstrating that the TPSCR system extended the pro-
ductivity over a longer period of time compared to the batch
mode. A further increase in productivity was achieved by in-
creasing the substrate concentration to 840 mm, which ena-
bled production of 11 gL1 of lauryl lactone after 72 h.
Recently it was shown that the use of unconventional media
can also improve or even inverse the enantioselective behavior
Scheme 11. Regiodivergent Baeyer–Villiger oxidation of substituted 1-inda-
nones by employing the isolated BVMOs from Pseudomonas fluorescens ACB
and the M446G mutant from Thermobifida fusca.[75] a) HAPMO / 5% hexane;
b) M446G PAMO/ 5% methanol.
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of BVMOs.[79] The first example of this was shown in the sulfoxi-
dation of alkyl aryl sulfides when employing purified HAPMO,
PAMO and the ethionamide monooxygenase from Mycobacteri-
um tuberculosis (EtaA).[80] Although the use of organic solvents
(30%, v/v) was found to diminish enzymatic activity to some
extent, this negative effect was counterbalanced by the in-
crease of the solubility of the starting sulfides in the unconven-
tional media. Moreover, when PAMO or EtaA were employed
as biocatalysts in the oxidation of thioanisole in 30% methanol
or ethanol, a significant increase in enantioselectivity was ob-
served, enabling the synthesis of methyl phenyl sulfoxide with
high optical purities (Scheme 12, Table 3). Moreover, the use of
methanol inversed the enantiopreference of PAMO when oxi-
dizing ethyl phenyl sulfide or phenyl propyl sulfide, yielding
the (R)-sulfoxides in excess instead of the (S)-sulfoxides. The
same behavior was also observed when adding 30% tert-butyl
methyl ether to the EtaA-catalyzed oxidation of thioanisole.
The effect of methanol in the PAMO-catalyzed oxidation was
analyzed in more detail. With only 1% of this cosolvent, it was
possible to increase the ee of the final sulfoxide from 43 to
68%. A further increase in the methanol concentration led to
(R)-methyl phenyl sulfoxide in 89% ee. The substrate concen-
tration did not alter the enantioselectivity of PAMO, and the
highest reaction rate (expressed as grams of substrate trans-
formed per L per h) was achieved at 20 gL1h1.
The performance of PAMO in the presence of organic cosol-
vents was also studied for the Baeyer–Villiger oxidation of a
set of racemic 3-phenylbutan-2-ones bearing different substitu-
ents in the aromatic ring.[81] Again, methanol triggered an im-
provement in the enantioselectivity of the kinetic resolution of
several 3-phenylbutan-2-ones. The best conditions in terms of
activity and E value were in 10–30% methanol. In the same
study, beneficial effects of organic cosolvents in the PAMO-se-
lective oxidation of a-acetylphenylacetonitrile to (R)-acetoxy-
phenylacetonitrile were found. No reaction was observed in
buffer with this ketone. However, the use of mixtures of aque-
ous buffer with 10% of water-immiscible solvents led to effec-
tive conversion. By using 10% EtOAc, it was possible to obtain
a 56% yield of enantiopure (R)-cyanoester after 72 h. Thus, be-
cause the starting material easily racemizes under these condi-
tions, an efficient DKR was performed by simply modifying the
reaction media.
The enzymatic Baeyer–Villiger oxidation of 2-alkyl-1-inda-
nones by using isolated M446G PAMO led to optically active 3-
alkyl-3,4-dihydroisocoumarins, which represent interesting in-
termediates in the preparation of biologically active com-
pounds. The use of relatively high pH and temperature al-
lowed the racemization of the starting material and resulted in
an effective DKR, leading to formation of the “unexpected” lac-
tones, as shown in Scheme 13.[82] Optimization of the reaction
conditions by exploring a set of organic solvents showed that
oxidations performed with 5% methanol led to the highest
conversions. However, the presence of this alcohol led to a
drop in the selectivities, whereas the addition of 5% hexane al-
Figure 1. CPDMO-biocatalyzed production of lauryl lactone (LL) from cyclo-
dodecanone by employing a two-phase semicontinuous reactor (TPSCR).[78]
Scheme 12. BVMO-catalyzed sulfoxidation of thioanisole and analogues by
using unconventional reaction media aqueous buffer/organic cosolvent.[79]
a) PAMO or EtaA, Tris-HCl, pH 9.0/cosolvent, G6P/G6PDH/NADPH, 250 rpm.
Table 3. Effect of organic cosolvents in the biocatalytic properties of
PAMO and EtaA when oxidizing prochiral sulfides.
R BVMO Cosolvent [%] c [%][b] ee [%][c] Config.
Me PAMO none 94 44 R
Me PAMO MeOH (1%) 83 68 R
Me PAMO MeOH (30%) 32 89 R
Me PAMO EtOH (30%) 9 48 R
Et PAMO none 79 33 S
Et PAMO MeOH (30%) 26 87 R
Pr PAMO none 56 19 S
Pr PAMO MeOH (30%) 9 56 R
Me EtaA none 43 33 S
Me EtaA MeOH (30%) 10 84 S
Me EtaA tBuOMe (30%) 11 26 R
[a] Yield after purification by column chromatography. [b] Determined by
GC. [c] Determined by HPLC.
Scheme 13. Synthesis of 3-alkyl-3,4-dihydroisocoumarins by dynamic kinetic
resolution employing M446G PAMO in unconventional reaction media.[83]
a) M446G, PAMO, Tris-HCl 50 mm, pH 10, 5% n-hexane or MeOH, G6P/
G6PDH/NADPH, 40 8C/250 rpm.
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lowed the chiral benzofused lactones to be recovered in the
highest optical purities; this demonstrates the beneficial effect
of organic cosolvents in some BVMO-catalyzed reactions. Oxi-
dations were more effective for those substrates with short
alkyl chains, leading to 3-methyl- and 3-ethyl-3,4-dihydroiso-
coumarins with conversion higher than 80%, whereas the
presence of longer chains produce a slight loss in conversions.
All the final products can be obtained with high to excellent
optical purities. Biooxidations were scaled up to 250 mg to
obtain the final 3-alkyl-3,4-dihydroisocoumarins, which repre-
sent interesting bioactive molecules.
Development of parallel interconnected kinetic asymmetric
transformations by using BVMOs
In Nature a huge number of chemically interconnected pro-
cesses concurrently take place, and the products are shared by
different metabolic routes, forming a complex and effective
metabolic network. In an attempt to mimic such efficient natu-
ral processes, concurrent catalytic concepts are being devel-
oped.[83, 84] Recently, a methodology has been developed, de-
scribed as parallel interconnected kinetic asymmetric transfor-
mation (PIKAT), which allows the concurrent preparation of
enantioenriched derivatives in a parallel way, with the advan-
tages of minimizing the quantity of reagents employed and
maximizing the redox economy of the process. In such an ap-
proach, two asymmetric transformations were coupled:
1) through two kinetic resolutions or 2) through a kinetic reso-
lution and a desymmetrization reaction. The PIKAT systems
were constructed by coupling of two redox biocatalysts (an
isolated ADH and an isolated BVMO) and by using a catalytic
amount of nicotinamide coenzyme. The coenzyme acts as con-
nector between the concurrent reactions. In a first approach,
isolated BVMOs (PAMO, its M446G mutant or HAPMO) cata-
lyzed the enzymatic kinetic resolution of a racemic benzylke-
tone while converting NADPH to NADP+ . This oxidized coen-
zyme was then internally recycled in a one-pot process by the
selective oxidation of a racemic secondary alcohol by using
the ADHs from Thermoanaerobacter sp (ADH-T) or from Lacto-
bacillus brevis (LBADH). As final reaction products, chiral sec-al-
cohols, benzylketones, and benzylesters were obtained
(Scheme 14A).[85] The reaction parameters were optimized to
achieve both kinetic-resolution processes with excellent enan-
tioselectivities. This concept was then extended to the desym-
metrization of a set of prochiral sulfides through BVMO-cata-
lyzed sulfoxidation coupled with the ADH-catalyzed kinetic re
solution of different racemic secondary alcohols.[86] By simply
changing the biocatalysts employed, the selectivity of the
system can be tuned. By using this methodology, a set of
chiral sulfoxides and chiral alcohols could be obtained with
high optical purities. One PIKAT example is given in
Scheme 14B, showing that all enantiomers of methyl phenyl
sulfoxide (30) and of octan-2-ol (31) can be obtained with ex-
cellent conversions and enantiomeric excesses by selecting the
right biocatalysts for the PIKAT system.
6. Applications of BVMOs in the Synthesis of
Biologically Active Compounds
The majority of the above-described oxidations were per-
formed with the goal of achieveing the synthesis of optically
active building blocks for the preparation of high value-added
compounds. In addition, BVMOs have been utilized for the
direct synthesis of biologically active compounds. Below, some
BVMO-mediated conversions that yield biologically active prod-
ucts are described.
Steroids represent an important class of natural products
with varying pharmacological properties, such as anticancer,
antiandrogenic, and antihypercholesterolemic activity. Minor
modifications in their structure can affect their biological activi-
ty. Consequently, numerous examples of new bioactive com-
pounds have been described by subtle steroid modifications,
in most of cases employing microorganisms. It has been
shown that strains of the genus Penicillium can perform steroid
transformations by means of reductions, hydroxylations, or
Baeyer–Villiger oxidations (Scheme 15A).[87] The BVMO activity
from Penicillium lilacinum AM111 is able to carry out D-ring oxi-
dation and degradation of steroids. Thus, dehydroepiandros-
terone (32) was oxidized to 3b-hydroxy-17a-oxa-d-homo-an-
drost-5-en-17-one (33) whereas androstenedione (34) was con-
verted into testololactone (35) in high yield. Baeyer–Villiger ox-
idation of pregnenolone (36) yielded a mixture of compounds,
Scheme 14. A) Parallel interconnected kinetic asymmetric transformation of
racemic benzylketones and racemic sec-alcohols by using BVMOs and ADHS;
and B) Enzymatic synthesis of all enantiomers of methyl phenyl sulfoxide
and rac-2-octanol catalyzed by HAPMO or M446G PAMO as BVMOs and the
alcohol dehydrogenases ADH-T or LBADH.[85]
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with 3b-hydroxy-17a-oxa-d-homo-androst-5-en-17-one (33) as
the major product and testololactone (35). This demonstrates
that the use of microbial isolates can be useful for selective
Baeyer–Villiger oxidations.
Only in a few cases has the use of isolated enzymes, such as
cytochrome P450s or BVMOs, been explored within steroid
transformations. Recently, isolated CPDMO from Pseudomonas
sp. has been screened for the biooxidation of a large number
of steroids.[88] Whereas this BVMO is involved in catabolism of
cyclopentadecanone in nature, it was found that it also accepts
steroids as substrates, as indicated in Scheme 15B. Thus, the
oxidation of 17-ketosteroids was achieved albeit with low
yields, yielding the corresponding normal lactones. The chemi-
cal Baeyer–Villiger oxidation of steroids bearing the carbonyl
group in the A-ring (3-ketosteroids) employing peracids led to
the formation of the 3-oxa-4-one-4a-homo products. The pecu-
liar regioselectivity of this oxida-
tion can be explained by the
attack of the peracid to the
less-hindered carbon due to the
chair conformation of the Crie-
gee intermediate. Biocatalyzed
Baeyer–Villiger oxidation with
CPDMO afforded the prepara-
tion of the opposite regioiso-
meric 3-one-4-oxa-4a-homolac-
tones for the first time, but with
low to moderate yields.
A BVMO-based methodology
has also been employed for the
preparation of the pharmaceuti-
cal ()-modafinil (37), a drug
employed for the treatment of narcolepsy and other sleep dis-
orders. Recently, the preparation of its key intermediate ()-(2-
benzyhydrylsulfinyl)acetic acid (38) has been described by em-
ploying isolated PAMO, which performs an enantioselective
sulfoxidation of prochiral ()-(2-benzyhydrylthio)acetic acid
(39 ; Scheme 16A).[89] The final product could be obtained with
complete conversion and good enantiomeric excess (85% ee).
The optical purity of the modafinil precursor can be slightly in-
creased by the addition of 10% methanol or isopropranol to
the reaction medium. Another promising example of BVMO-
mediated synthesis of a pharmaceutical is the use of an engi-
neered BVMO for preparing esomeprazole, a proton-pump in-
hibitor (PPI) and multibillion dollar drug. Esomeprazole (40), a
substituted pyridylmethylsulfinyl benzimidazole, is widely used
for the treatment of acid-related diseases. Recently, a BVMO
has been optimized by directed evolution to effectively per-
Scheme 15. Enzymatic Baeyer–Villiger oxidation of steroids catalyzed by BVMOs: A) Employing whole cells of P. lilacinum AM111,[87] and B) Isolated CPDMO-
biocatalyzed oxidation of 17-keto- and 3-ketosteroids.[88] For this latter enzyme, Baeyer–Villiger reaction led to the formation of the 3-one-4-oxa-4a-homolac-
tones, a regioisomeric product to the one obtained by employing peracids. a) CPDMO; b) G6P/G6PDH, NADPH.
Scheme 16. A) Chemoenzymatic synthesis of ()-modafinil employing as key step a PAMO-catalyzed sulfoxida-
tion;[89] B) Biocatalyzed preparation of esomeprazole by using an evolved Baeyer–Villiger monooxygenase.[90]a) PA-
MO/buffer, G6P/G6PDH.
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form the enantioselective sulfoxidation of omeprazole (41),
leading to esomeprazole (Scheme 16B).[90]
Biocatalytic reactions are receiving increasing interest when
these green chemistry methodologies can be integrated in sus-
tainable strategies. Thus, a combined photochemical and bio-
catalytic methodology has been employed for the synthesis of
bicyclo[4.2.0]octanes, a structural moiety that is widely spread
in natural products and that is difficult to prepare by conven-
tional chemical methodologies. The Cu-catalyzed [2+2] photo-
cycloaddition of the O-tert-butyldimethylsilyl-protected 1,3-di-
vinyl-2-cyclopentanol proceeded smoothly with high endo dia-
stereoselectivity. Cleavage of the protecting group and oxida-
tion of the resulting alcohol led to the bridge ketone, which al-
lowed for several cleavage protocols. The microbial Baeyer–
Villiger oxidation was found to be the most appealing ap-
proach in order to achieve good conversions.[91] The formation
of enantiocomplementary lactones was found to depend on
the enzyme used. By selecting the proper BVMO it is possible
to get access to antipodal lactones with good to excellent
enantiomeric excess. The final molecule, bicyclo[4.2.0]octane,
was obtained after lactone hydrolysis.
The preparation of the oxabicycloketone by a sonochemical
[4+3] cycloaddition of furan and tetrabromoacetone with sub-
sequent reductive dehalogenation afforded the interesting
prochiral compound 42 in a single operation. This ketone was
selectively oxidized by CPMOComa, leading to the chiral (+)-
(1S,6S)-lactone 43 with high optical purity in a desymmetriza-
tion that introduces two stereogenic centers into the molecule,
as indicated in Scheme 17.[92] After optimizing the fermentation
conditions, an isolated yield of 70% can be achieved. The final
product, presenting high functional diversity and structural ri-
gidity, has been employed as starting material for the prepara-
tion of various natural products containing a tetrahydrofuran
structural motif. Thus, the total syntheses of the antibiotic (+)-
showdomycin (confirming the absolute configuration of the
bio-oxygenation product) and the metabolite trans-kumausyne
were described, as well as the formation of precursors of the
cytotoxic metabolite goniofuranone and analogues. It is inter-
esting to note that CHMOXantho is also able to convert the car-
bocyclic analogue of compound 42 in >99% ee, which, in
principal, allows access into the corresponding carbocyclic
compound series.[29]
The BVMO-catalyzed oxidation of prochiral cyclobutanones
provides access to chiral butyrolactones, a highly versatile plat-
form to synthesize natural products and bioactive molecules
with great structural diversity, like GABA receptor inhibitors, b-
amino acids, lignans, or antagonistic analgesics. Several ketone
precursors, prepared by a straightforward [2+2] cycloaddition,
were oxidized by E. coli cells expressing the CHMO- and CPMO-
type BVMOs.[93] The BVMO collection allowed access to enan-
tiocomplementary butyrolactones (Scheme 18) with optical pu-
rities ranging from moderate to excellent. Biooxidation of n-
butylcyclobutanone yielded exclusively the (S)-butyrolactone
with good yields for all the BVMOs tested. In most cases con-
version of aryl cyclobutanones led to ()-lactones in good op-
tical purities, with the enantiocomplementary lactones accessi-
ble via CHMOBrevi2. p-Chlorophenylbutyrolactone, an important
intermediate in the preparation of GABA, was also obtained
with high optical purities in both antipodal stereoisomers de-
pending on the BVMO used. Another interesting substrate is
piperonylcyclobutanone. The ()-lactone was obtained in high
enantioselectivity with most of the BVMOs tested, with the ex-
ception of the biocatalysts belonging to the CPMO-type clade
(CPMOComa and CHMOBrevi2). The antipodal (+)-lactone can be
isolated with moderate selectivity by employing CHMOBrevi1.
E. coli cells expressing HAPMO have also been employed in the
biocatalyzed oxidation of prochiral 3-substituted cyclobuta-
nones. For all compounds tested, moderate to good yields of
the chiral butyrolactones were obtained. The stereoselectivity
appears to be strongly dependent on the distance of the sub-
stituents to the carbonyl group. A phenyl group induces good
enantioselectivity, whereas the presence of a benzyl group or
branched alkyl chains led to a decrease in HAPMO selectivity.
7. Baeyer–Villiger Monooxygenases in Newly
Identified Metabolic Pathways
Mithramycin, an aureolic acid-type anticancer drug and calci-
um-lowering agent produced by Streptomyces argillaceus and
other streptomycetes, contains a polyketide-derived tricyclin
core. Its biosynthesis proceeds through the condensation of
Scheme 17. Chemenzymatic synthesis of tetrahydrofuran-based compounds
employing as key step a Baeyer–Villiger oxidation catalyzed by CPMOComa.
[92]
Scheme 18. Chemoenzymatic preparation of chiral butyrolactones as start-
ing material for the synthesis of biologically active compounds.[93] a) Zn,
AcOH; b) microbial BVMO.
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multiple acyl-CoA units catalyzed by a type II polyketide syn-
thase to form the intermediate premithramycinone. This pre-
cursor is glycosylated and C-methylated to afford premithra-
mycin B (44), which undergoes an oxidative cleavage in its
fourth ring, followed by decarboxylation and reduction of the
4’-keto group.[94] Experiments with isotopically labeled precur-
sor have suggested that the key oxidative cleavage proceeds
through a Baeyer–Villiger oxidation. To confirm this hypothesis,
the monooxygenase MtmOIV was overexpressed, isolated, and
employed as a biocatalyst in the conversion of premithyramy-
cin B.[95] The first step in the premithyramycin B transformation
was found to be the formation of the premithramycin B lac-
tone (45 ; Scheme 19A), which confirms the role of MtmOIV as
a BVMO. Overexpression of this enzyme was achieved by clon-
ing the respective gene into an E. coli expression vector. Char-
acterization of MtmMOIV confirmed that it is a FAD and
NADPH-dependent monooxygenase. The crystal structure of
this BVMO has recently been determined by X-ray crystallogra-
phy.[96] The MtmOIV structure shows significant differences
when compared with the elucidated structures of CHMO from
Rhodococcus sp. strain HI-31 and PAMO. This is in line with the
fact that MtmOIV belongs to another flavoprotein monooxyge-
nase class. In fact, it has been postulated that MtmOIV is a rep-
resentative of a newly recognized class of BVMOs.
The g- and d-lactones contribute to the flavor of many fruits
and dairy products, which are produced from fatty acids by
plants and microorganisms. These compounds were assumed
to be stable end products, but further investigations have re-
vealed than in the presence of the lactone-producing yeast
Sporobolomyces odorus, these final compounds were also trans-
formed.[97] The catabolic pathway of such lactone degradation
has been elucidated by employing labeled compounds.
S. odorus was shown to be able to degrade 4- and 5-hydroxy-
decanoic acids and esters by oxidation to the corresponding
oxoacids or oxoesters, which are subsequently transformed by
a Baeyer–Villiger oxidation. Thus, BVMO activity for a yeast has
been described for the first time. Nevertheless, the responsible
enzyme of this biotransformation has not yet been deter-
mined.
For decades, thioamides have been employed to treat tuber-
culosis infections. In 2000, it was first demonstrated that in
M. tuberculosis the antimycobacterial activity of the most
widely used thioamide, ethionamide (46), requires enzymatic
activation.[98] Thus, it was recognized that S-oxygenation of the
thiourea moiety of ethionamide was involved in its bioactiva-
tion to a toxic metabolite, which determines the therapeutic
effect. The gene product Rv3854c (ethionamide monooxyge-
nase, EtaA) of M. tuberculosis was identified as the enzyme re-
Scheme 19. Some examples of metabolic pathways in which BVMOs are involved: A) Baeyer–Villiger oxidation of premithyramycin B into premithramycin B
lactone catalyzed by MtmOIV.[95] B) EtaA-catalyzed activation of the prodrug ethionamide (46).[98] C) Activation of isoxyl (49) by a double oxidation catalyzed
by EtaA and formation of the proposed activated form formimidamide 51,[100] and D) PtlE-catalyzed Baeyer–Villiger oxidation of 1-deoxy-11-oxopentalenic acid
in the methabolic pathway of pentalenolactone.[103]
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sponsible for the bioactivation of ethionamide. Ethionamide
monooxygenase was characterized as a FAD-containing
enzyme capable of transforming ethionamide into two major
products, the S-oxide 47 and 2-ethyl-4-amidopyridine. Ethiona-
mide and its S-oxide present equivalent therapeutic potency
and hepatoxicity, whereas 2-ethyl-4-amidopyridine is relatively
nontoxic and without therapeutic efficacy. Further oxygenation
of the S-oxide to the sulfinic acid 48, which spontaneously
breaks down to 2-ethyl-4-amidopyridine and other products, is
the postulated pathway for bioactivation of ethionamide in
M. tuberculosis (Scheme 19B). The sulfinic acid, an unstable in-
termediate, is supposed to be the key target in the toxicity
and has not been isolated. The EtaA sequence contains a
BVMO-identifying fingerprint, which triggered a study to estab-
lish whether EtaA represent a bona fide BVMO. This revealed
that it indeed is able to catalyze Baeyer–Villiger reactions with
a wide set of aliphatic and aromatic ketones, and it also cata-
lyzes enantioselective oxidation of methyl p-tolyl sulfide.[80]
EtaA is also able to convert other prodrugs, such as isoxyl and
thiacetazone, into reactive species against M. tuberculosis.[99]
Jackson and co-workers have recently demonstrated that the
EtaA-catalzyed oxidation of isoxyl 49 is required for this pro-
drug to inhibit its lethal enzymatic targets in M. tuberculosis.[100]
An analysis of the metabolites obtained from the in vitro trans-
formation of isoxyl by isolated EtaA revealed the presence of a
formimidamide 51 and the urea 50 derivative as final products,
as shown in Scheme 19C. It has been proposed that the formi-
midamide is the activated form of isoxyl. The activation path-
way is proposed to be triggered by EtaA-catalyzed successive
sulfide oxidations, leading to compounds 52 and 53. Interest-
ingly, the Baulard group has shown that by targeting the regu-
lator for EtaA expression, the transcriptional repressor EthR,
with specific inhibitors, the efficacy of thioamide-based treat-
ment can be improved.[98a]
Aflatoxins are a group of polyketide-derived secondary me-
tabolites produced mainly by certain molds, for example, As-
pergillus flavus and Aspergillus parasiticus. These compounds
are highly toxic and carcinogenic in animals and humans. The
biosynthetic pathway of aflatoxins has been extensively stud-
ied.[101] Various genes and corresponding enzymes involved in
aflatoxin biosynthesis from coenzyme A have been described.
It has been established that 25 genes involved in this biosyn-
thetic feat, are clustered within a 70 kb DNA region in the
chromosomes of A. parasiticus and A. flavus. Expression of
most of these genes is regulated by the regulatory genes aflR
and aflJ. Recently, the function of one of the genes (moxY)
present in the aflatoxin gene cluster has been elucidated by
disrupting the gene in A. parasiticus NRRL 2999. It was discov-
ered that the moxY gene encodes the hydroxylversicolorone
monooxygenase, which catalyzes the Baeyer–Villiger oxidation
from hydroxyversicolorone to versiconal hemiacetal acetate,
metabolites in the aflatoxins biosynthesis. This confirmed the
role of a BVMO in this metabolic pathway.
The sesquiterpenoid antibiotic pentalenolactone (54), isolat-
ed from more than 30 Streptomyces species, possesses activity
against both Gram-positive and Gram-negative bacteria as well
against pathogenic and saprophytic fungi. Streptomyces aver-
mitilis is a Gram-positive soil bacterium that produces a variety
of secondary metabolites. Although pentalenolactone has not
been detected in the organic extract of S. avermitilis, the shunt
metabolite pentalenic acid has been isolated. This microorgan-
ism contains a 13.4 kb gene cluster containing 13 unidirection-
ally transcribed open-reading frames corresponding to the ap-
parent biosynthetic operon for pentalenolactone.[102] One of
these genes encodes a protein that contains the typical BVMO-
identifying motif. In a recent study this protein, PtlE, was re-
combinantly produced and tested for conversion of 1-deoxy-
11-oxopentalenic acid. The enzyme was supposed to catalyze
the Baeyer–Villiger oxidation of this complex ketone into the
corresponding lactone, pentalenolactone D.[103] However, al-
though it was found that recombinant PtlE catalyzes a Baeyer–
Villiger oxidation of 1-deoxy-11-oxopentalenic acid (55), the ex-
pected lactone was not formed. Instead, lactone 56 is formed
in which the oxygen insertion is opposite to the expected out-
come (Scheme 19D). This final product, neopentalenolac-
tone D, represents a new branch of the pentalenolactone
family tree.
Gordonia sp. strain TY-5 is an actinomycete capable of aero-
bic growth on gaseous propane as a carbon and energy
source. This microorganism was able to use also acetone as
source of carbon and energy. Recently, a study conducted to
characterize acetone metabolism in Gordonia sp. at enzymatic
and gene levels revealed the presence of two acetone-induced
proteins. Their corresponding genes acmA and acmB encoded
a Baeyer–Villiger monooxygenase and an esterase, respective-
ly.[105] These enzymes enable the microorganism to transform
acetone into methyl acetate, which is subsequently hydrolyzed
to acetate and methanol. The acmAB gene cluster plays an im-
portant role in the metabolism of acetone derived from pro-
pane oxidation and clarifies the propane metabolic pathway of
this Gordonia strain (propane!propan-2-ol!acetone!methyl
acetate!acetic acid/methanol). Acetone monooxygenase
(AcmA) was then purified revealing that it is a NADPH-depen-
dent BVMO of 63 kDa showing activity towards cycloketones
and aliphatic linear ketones.
The microbial genome sequences provide nowadays a
wealth of information about new BVMOs. However, for effec-
tive genome mining for novel biocatalysts it is necessary to
have tools for a reliable identification of genes that encode
BVMOs. The above-mentioned BVMO-identifying sequence
motif has proven to be very helpful in identifying novel BVMO
genes.[10] The first example of a BVMO discovered by this ap-
proach was PAMO from Thermobifida fusca, which has been
cloned, overexpressed in E. coli and employed for various se-
lective Baeyer–Villiger reactions and sulfoxidations (vide
infra).[53] The enzyme shows highest activity with aromatic
compounds. Genes surrounding the pamo gene on the
genome are predicted to play a role in degradation of aromat-
ic compounds. This suggests that PAMO is involved in catabo-
lism of aromatic compounds, possibly derived from lignin as
T. fusca was recently suggested to participate in lignin degra-
dation. The metabolic roles of BVMOs harvested in other
genome-mining studies remain unclear. Nevertheless, Grogan
and co-workers have convincingly shown by two BVMO discov-
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ery studies that the approach of mining genomes can be very
powerful in obtaining valuable novel BVMOs.[105] By using liga-
tion-independent cloning procedures,[106] 29 BVMO genes have
been cloned from the genomes of M. tuberculosis and Rhodo-
coccus jostii RHA1. Heterologous expression of soluble BVMOs
in E. coli was achieved for about half of these genes. Whole
cells expressing these genes have been screened for the oxida-
tion of bicyclo[3.2.0]hept-1-en-6-one. This uncovered a wide di-
versity of regio- and/or enantioselective behavior. Analysis of
the protein sequences of the Rhodococcus enzymes combined
with the biocatalytic results has allowed grouping of these
BVMOs as well as identifying group-specific protein sequences
to BVMO. Such comparative analyses of sequence-related
BVMOs are valuable to develop more reliable tools to predict
catalytic properties of novel BVMOs.
8. Recent Methodologies for the Optimization
of the BVMO-Biocatalyzed Processes
Enzyme engineering
Nowadays, powerful methodologies exist to redesign enzymes
to meet specific demands. Directed evolution approaches in-
volve the (semi-)random mutagenesis of enzymes and subse-
quent screening for enzyme mutants with improved features.
This approach has shown to be very effective to alter almost
any enzyme characteristic. Only a limited number of BVMO re-
design studies have been reported so far. The Reetz group was
the first to report on the directed evolution of CHMOAcineto.
[107]
The gene encoding CHMOAcineto was subjected to error-prone
PCR, after which relatively small mutant libraries (10000) were
screened for mutant CHMOs that displayed improved enantio-
selectivity for 1) Baeyer–Villiger oxidation of 4-hydroxycyclo-
hexanone, and 2) sulfoxidation of methyl p-tolyl sulfide. Oxida-
tion of prochiral 4-hydroxycyclohexanone results in formation
of the corresponding seven-membered lactone, which sponta-
neously rearranges to form the final hydroxy butyrolactone
with no change in stereochemistry. The wild-type CHMOAcineto
only shows 9% ee for formation of the R enantiomer. Upon
screening 10000 mutants, 24 mutants were shown to have an
increased R selectivity whereas 12 displayed reversal of enan-
tioselectivity. Optimization of the R selectivity by a second
round of epPCR allowed creation of a quadruple mutant that
catalyzed the Baeyer–Villiger oxidation with 90% ee. When
wild-type CHMOAcineto is used for oxidation of prochiral methyl
p-tolyl sulfide the (R)-sulfoxide was obtained with only 14% ee.
Several mutants were found from the same library as above
with significantly improved enantioselectivity (ee values
>95%), some being R and others being S selective.[108] Inter-
estingly, one of the best mutants for enantioselective sulfoxi-
dation was F432S whereas mutations of F432 were also found
when looking for mutants with improved enantioselectivity for
oxidation of 4-hydroxycyclohexanone. In a subsequent study, a
set of the generated CHMOAcineto mutants was selected, which
displayed enantiocomplementary for the Baeyer–Villiger reac-
tion of other structurally different ketones such as prochiral 3-
substituted cyclobutanones, 4-substituted cyclohexanones,
and bi- and tricyclic ketones.[109] For almost all the substrates,
mutants that contained a F432 mutation had a strong effect
on the biocatalytic properties of CHMO. Therefore this residue
can be regarded as a “hot spot” for tuning selectivity of
CHMOAcineto. Identification of such hot spots offers the possibili-
ty to focus enzyme-engineering efforts. Focusing the randomi-
zation in mutant libraries can also be inspired by analysis of
enzyme structures. An example of this is the study in which
CPMOComa has been also subjected to mutagenesis in order to
find new mutants with improved enantioselectivities.[110] By
comparison of a homology model of this enzyme with the
crystal structure of PAMO several residues were selected for
preparing mutant libraries. By this approach, mutants were ob-
tained that showed significant improvement in enantioselectiv-
ity with 4-substituted cyclohexanones.[77] Another even more
focussed engineering effort has been the structure-inspired
site-directed mutagenesis of PAMO. By targeting several active-
site residues by site-directed mutagenesis, the M446G mutant
was discovered that exhibits a significantly changed substrate
spectrum and improved enantioselectivity for, for example, sul-
foxidation reactions. It was also the first example of a BVMO
that is able to convert indole into indigo blue.[56] Reetz has fo-
cused mutagenesis efforts in the same structural area, the loop
region 440–447 in PAMO (which also includes the position of
F432 in CHMO), to alter the catalytic properties of PAMO
(Figure 2).[111] First, deletion mutants were made to enlarge the
active site; this resulted in mutants that displayed activity to-
wards more bulky ketones. Subsequent semi-random muta-
genesis studies have targeted several residues in this loop
region revealing that this part of the protein is crucial in form-
ing the substrate-binding site. In a recent study, mutations
that are relatively far from the active site of PAMO and on the
surface of the protein have been engineered that still affected
the catalytic behavior.[112] The fact that distant mutations in
Figure 2. Crystal structure of PAMO with the FAD cofactor in sticks and the
440–447 loop region in dark gray.
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PAMO can affect enzymatic properties might reflect the dy-
namic events that are involved in BVMO-mediated catalysis.
The recently elucidated structures of CHMO from Rhodococcus
sp. strain HI-31 and the PAMO structural and kinetic data indi-
cate that during the catalytic cycle of these BVMOs, major con-
formation changes occur.[15,16] For more focused BVMO rede-
sign studies, it will be crucial to obtain a better understanding
of this dynamic behavior.
Whereas the engineering efforts above focussed on altering
the substrate specificity and enantioselectivity, some BVMO en-
gineering has also been performed to alter the coenzyme spe-
cificity. Unfortunately, these site-directed mutagenesis studies
have not yet resulted in a BVMO that is efficient with
NADH.[113]
Scaling up methodologies
The use of Baeyer–Villiger monooxygenases for synthetic pur-
poses is highly attractive when compared with the convention-
al chemical Baeyer–Villiger oxidations.[114] Apart from the high
chemo-, regio-, and/or enantioselectivities of BVMOs, the op-
erational conditions for BVMO-mediated conversions are mild
and environmentally friendly with air as oxidant. However, the
implementation of BVMOs at an industrial level is not yet well
developed. One of the major hurdles is the fact that BVMOs
depend on the reduced nicotinamide coenzyme NADPH for ac-
tivity. One of the easiest ways of dealing with this requirement
is the use of whole cells. In such fermentation set-up one relies
on the NAD(P)H recycling activity of metabolically active cells.
This is typically achieved by feeding the cells with a cheap
carbon source together with the target substrate.
However, employing the wild-type strain often presents dis-
advantages. In the case of CHMOAcineto, these are low activities,
handling of a pathogen and the presence of undesired side re-
actions. For these reasons, the implementation of whole-cell
processes has been facilitated by the use of recombinant cells
overexpressing the desired enzymes.[64b,115] Host strains ideally
exhibit fast growth rates, lack interfering activities, and support
efficient coenzyme regeneration. E. coli strains fulfil these re-
quirements and have been used for whole-cell transformations.
However, a number of limitations have been identified when
analyzing the biooxidation of the model substrate bicyclo-
[3.2.0]hept-2-en-6-one by recombinant E. coli.[116] The reaction
is inhibited by the substrate at concentrations higher than
1.0 gL1 and by the final products at levels of 3.5 gL1. Further-
more, the biocatalyst concentration and the oxygen supply
were found to be bottlenecks. The effect of the biocatalyst
concentration has been studied by employing fresh E. coli
TOP10 cells expressing CHMOAcineto. At low cell concentrations,
there was a linear increase in the initial reaction rate, but once
a certain maximum rate was achieved, a steady decrease in the
rate was observed as a function of the cell concentration. Be-
cause molecular oxygen is required not only as metabolic sub-
strate for cell maintenance but also for the biocatalyzed oxida-
tion, when the cell concentration is high and oxygen becomes
a limiting factor, oxygen is used preferentially by E. coli for its
metabolism.[117] Thus, oxygen-limited conditions led to a dra-
matic decrease in space–time yields. Methods for enhancing
oxygen mass transfer consist in a longer bubble residence
time, the formation of smaller air bubbles to increase the inter-
face area or the use of oxygen-enriched aeration. Except for
finding an effective oxygen supply, also tuning the metabolic
state of the cells is of importance. For this reason, nongrowing
conditions were initially developed for E. coli cells expressing
CHMOAcineto by growing the cells until the stationary phase.
[118]
After that, cells are harvested and resuspended in a minimal
salt medium lacking a nitrogen source. In these conditions, the
cell replication is inhibited while the cellular machinery is still
able to regenerate NADPH and to act as a catalyst.[119] Non-
growing conditions have recently been employed in biooxida-
tions catalyzed by E. coli whole cells expressing CHMOAcineto,
CPMOComa, and some of their mutants. The scaling up of the re-
actions under these conditions led to a high increase in the
conversions for several 4-substituted cyclohexanones. In addi-
tion, the use of resting cells gave the optically active lactones
in good yields for a number of substrates for which no reac-
tion was previously observed. By this it was possible to obtain
both enantiomeric lactones depending on the biocatalyst em-
ployed. The conversion efficiency was superior when com-
pared with the use of growing cells. This can be explained by
a better balance of BVMO activity and other metabolic activi-
ties and a more effective substrate transport in nongrowing
cells due to an increased membrane permeability caused by a
high concentration of hydrophobic substrate and product in
the reaction medium.
A significant improvement in conversion efficiency was final-
ly developed by the resin-based in situ substrate-feeding prod-
uct-removal method (SFPR, Figure 3).[120] This methodology em-
ployed an adsorbing polymeric resin that acts as a reservoir for
the starting material and as a trap for the final product. The
substrate is loaded into the reactor before performing the bio-
transformation. It diffuses into the reaction medium and is
transformed by the added recombinant cells, whereas the
formed product will be readsorbed onto the same resin. The
system is conveniently tuned by a proper selection of the sub-
strate/resin ratio. Thus, both the substrate and product con-
centrations are controlled in order to maintain them below
their inhibitory or toxic levels and allow a higher productivity.
Figure 3. The in situ substrate-feeding product-removal (SFPR) concept ap-
plied to the Baeyer–Villiger oxidation of ketones catalyzed by BVMOs.[121]
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SFPR methods have been described previously, but Hilker et al.
have applied the concept to a BVMO-catalyzed oxidation for
the first time: the Baeyer–Villiger reaction of the racemic
ketone ( )-bicyclo[3.2.0]hept-2-en-6-one by CHMOAcineto.[121] For
optimization, 14 resins were tested by looking for an adsorb-
ent with a high capacity at the equilibrium concentration for
the biotransformation. The best results were obtained with the
Dowex Optipore L493 resin. Product can be recovered from
the resin by washing with a polar solvent or by soxhlet extrac-
tion. The resin can be reused after washing with methanol and
water. Three types of reactors, one conventional, a recycle re-
actor, and a bubble column reactor were studied and com-
pared. The best one proved to be the bubble column, with
which 25.0 g (0.23 mol) of starting ketone was completely oxi-
dized by using a one-liter vessel with a volumetric productivity
of about 1.0 gL1h1. This led to nearly exclusive production
of the two corresponding regioisomeric lactones with high
yield and excellent enantiomeric excess (ee >98%). An addi-
tional benefit of an in situ SFPR methodology is the opportuni-
ty to continue the biotransformation even in case of loss of
cell activity. As most of the substrate and product are stored in
the resin, exhausted cells can be replaced by fresh ones by
simply decanting the resin. Thus, the use of SFPR systems ena-
bled the non-natural substrate toxicity to expression hosts,
enzyme inhibition, and biocatalyst stability to be overcome as
the most critical aspects of BVMO-mediated biotransforma-
tions.
The SFPR approach has been also employed for the oxida-
tion of three ketones employing E. coli cells expressing
CPMOComa.
[122] The model reaction was the oxidation of prochi-
ral 4-methylcyclohexanone to the corresponding lactone. First,
the optimal substrate concentration for this reaction was de-
termined (3.4 gL1). The optimization of other parameters re-
sulted in the use of a reduced oxygen saturation 50–30%, and
the addition of glucose (4.0 gL1) after induction of protein
production. Also the addition of a b-cyclodextrin was beneficial
because it improves the substrate transport into the cell and/
or serves as a reservoir for the substrate within the fermenta-
tion broth. In the best reaction conditions, a total yield of 84%
was achieved. Again, the use of nongrowing conditions also
resulted in higher yields with respect to the biotransformation
in growing conditions. Subsequently, preloaded resin Lewatit
VPOC 1163 was used to develop the SFPR processes. By using
this, 10 gL1 of 4-methylcyclohexanone can be converted by
CPMO-growing cells with a 77% yield after 26 h, whereas the
use of nongrowing conditions allowed to transform 15 gL1 of
the same substrate with 86% yield after 20 h of fermentation
time. The latter represents a fivefold increase in substrate con-
centration and an improved yield compared with the results
from growing-cell systems without the SFPR methodology.
This study was then extended to the biooxidation of 3-methyl-
cyclohexanone which was regioselectively oxidized to the
proximal lactone. Reaction with 15.0 gL1 of this ketone led to
80% yield after 10 h. 8-Oxabicyclo[3.2.1]oct-6-en-3-one can be
oxidized to the corresponding lactone, an interesting and ver-
satile intermediate. Previous attempts to perform the whole-
cell biotransformation of this ketone were developed at
2.0 gL1, as higher concentrations elicited product inhibition.
SFPR represented an effective alternative to the preparation of
this interesting lactone: after 22 h a 78% isolated yield was
achieved. SFPR has recently also been employed for enantiose-
lective kinetic resolution of the aromatic ketone, ( )-3-phenyl-
2-butanone.[123]
The examples above show that the SFPR approach can be
very effective. Nevertheless, some SFPR-related limitations
have to be considered, for example, limitations due to the sub-
strate/product couple. The adsorption/desorption equilibrium
on a given resin depends on the physicochemical properties of
the compounds, so they have to be compatible with the de-
manded working concentrations. Also, not every substrate or
product will easily cross the cell membrane, and this prohibits
the use of whole cells.
The alternative approach by immobilizing recombinant
whole-cell expression systems was proposed very recently and
certainly requires future attention based on favorable initial re-
sults.[124]
Self-sufficient biocatalysts
Whole (recombinant) cells are frequently used in industry for
biocatalytic processes. However, in particular cases other ap-
proaches are necessary, for example, when substrate and/or
product are toxic to cells or cannot pass the cell membrane. To
circumvent such problems the use of isolated enzymes might
be a solution. This approach presents some advantages, as af-
fording clean, effective, and simple reactions. But, when deal-
ing with redox enzymes, these processes typically require
redox coenzymes. In case of BVMOs, the relatively unstable nic-
otinamide coenzyme NAD(P)H is essential for BVMO activity.
Because NADPH is an expensive compound, it cannot be ap-
plied stoichiometrically. Therefore, several coenzyme regenera-
tion methods that allow the catalytic use of NADPH have been
developed. A good NADPH regeneration system should meet
several criteria such as low cost, no risk of byproducts, and no
interference with the biocatalytic properties of BVMOs. The
most frequently employed approach includes utilization of iso-
lated enzymes by coupling a second enzymatic system (glu-
cose-, glucose-6-phosphate, formate, phosphite or alcohol de-
hydrogenases) to the BVMO-catalyzed oxidation.[125] The dehy-
drogenase will regenerate NADPH at the expense of a sacrifi-
cial substrate, for example, glucose. Recently, this approach
was refined in our labs by fusing a dehydrogenase to individu-
al BVMOs (Scheme 20).[126] Fusion proteins have been exploited
in the last years for protein purification, but have not been
used extensively for biocatalytic purposes.[127] The recently de-
scribed phosphite dehydrogenase (PTDH) was selected as a
fusion partner for BVMOs.[128] This bacterial enzyme catalyzes
oxidation of phosphite into phosphate in a quasi-irreversible
process during which it reduces NADP+ to NADPH. Initially,
three fusion biocatalysts (CRE/BVMOs) were prepared by using
PAMO, CHMOAcineto, and CPMOComa as fusion partners for PTDH.
Analysis of the created CRE/BVMOs revealed that fusing the
BVMOs with PTDH did not significantly alter their catalytic
properties or thermostability. Also, no inhibition of either the
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BVMOs or PTDH by the involved substrates or products was
observed. CRE/CHMO and CRE/CPMO were applied as whole
cells or as crude cell-free extracts in enantioselective oxidations
by using prochiral as well as racemic ketones as starting mate-
rials. This revealed that the stereoselectivity of the fused
BVMOs was not affected. The data also showed that the fusion
of PTDH as a coenzyme-regenerating enzyme does not inter-
fere with BVMO functioning. As an appealing side note, prepa-
rative biotransformations can be carried out by using crude
cell-free extract without addition of NADP+ because sufficient
quantities of the coenzyme seem to be present in E. coli cells ;
this represents a significant simplification in the experimental
protocol and potential future development of these biocata-
lysts.
One drawback of the CRE/BVMOs was the relatively poor
stability of the PTDH subunit. To solve this, a second genera-
tion of self-sufficient biocatalyst was prepared involving three
important modifications: 1) a thermostable mutant of PTDH for
effective coenzyme regeneration was used as N-terminal fusion
partner,[129] 2) a codon optimized PTDH gene for improving the
expression in E. coli was used, and 3) a sequence for a histidine
purification tag at the free N terminus of PTDH was integrated
in the expression vector. Six 2nd generation fusion proteins
(CRE2/BVMOs) were prepared by using CPMO, CHMO, HAPMO,
EtaA, PAMO, and its M446G mutant.[130] Again, the purified
CRE2-BVMOs display similar kinetic parameters when com-
pared with the nonfused enzymes. The fused biocatalysts have
been employed as cell-free extracts for the conversion of
bicyclo[3.2.0]hept-2-en-6-one, which revealed that the robust-
ness of these CRE2/BVMOs does not depend anymore on
PTDH stability.
Other advances in regeneration systems
In the last few years, some methodologies have been devel-
oped to circumvent the need for nicotinamide coenzymes in
BVMO-catalyzed reactions. These methods aim at direct regen-
eration of the flavin cofactor of BVMOs and involve chemical
or the photochemical cofactor regeneration.
The rhodium complex [Cp*Rh(bpy)(H2O)]
2+ , first synthesized
by Steckhan and co-workers,[131] has been widely applied for
the reduction of flavins, porphyrins, and nicotinamides and has
been employed as a regeneration reagent in reactions cata-
lyzed by oxidoreductases.[132] In the presence of a formate salt,
this complex leads to [Cp*Rh(bpy)H]+ , which is able to act as
an electron donor capable of reducing a flavin cofactor. Thus,
[Cp*Rh(bpy)(H2O)]
2+ has been employed in the enzymatic oxi-
dation of prochiral sulfides by using PAMO, HAPMO,
CHMOAcineto, and EtaA.
[133] When the complex was employed as
coenzyme substitute, it was able to directly reduce the
enzyme-bound FAD, but the activity and selectivity displayed
by the BVMOs under these conditions were very low. The pres-
ence of NADP+ in the reaction medium could restore the activ-
ity and selectivity of the BVMOs to some extent. Nonetheless,
using chemical regeneration with these reactions led to worse
results than when employing the enzymatic regeneration of
NADPH due to inefficient delivery of reducing equivalents. The
results confirmed the dual role of the NADP+ coenzyme: it
serves as an electron donor while it also is part of the active
site during the oxidation reaction. Kinetic and structural data
have shown that the NADP+ stays bound throughout the cata-
lytic cycle after flavin reduction until it is replaced by NADPH.
The bound NADP+ exerts a positive effect on the stability of
the peroxyflavin intermediate and also is crucial for enantiose-
lectivity, presumably by direct or indirect interaction with the
bound substrate. Therefore, for a fully effective and selective
BVMO, a catalytic amount of NADP+ will always be advanta-
geous.
Recently, an attractive photochemical approach has been
described by Hollman et al. for the flavin regeneration in
BVMO-biocatalyzed reactions, with the aim of avoiding the use
of the expensive nicotinamide coenzyme.[134] Photochemical re-
generation of cofactors is a highly attractive approach because
it enables the exploitation of solar light as a cheap and envi-
ronmentally friendly reagent. To generate light-driven electron
transfer, photosensitive material is required such as organome-
tallic complexes, flavins, and semiconductors. Such compounds
promote electron generation by using suitable electron
donors, for example, EDTA or mercaptoethanol (Scheme 21).
The PAMO-P3 mutant has been tested as a biocatalyst in the
enzymatic oxidation of prochiral ketones by using solar light,
EDTA, and an additional flavin as electron mediator. As could
be expected (vide supra), in the absence of nicotinamide coen-
zyme, no enzymatic oxidation was observed. Addition of small
amounts of NADP+ afforded the conversion of 2-phenylcyclo-
hexanone into (S)-2-phenylcaprolactone with excellent enantio-
meric excess (ee=97%) and 48% conversion, showing that the
selectivity of this BVMO is not altered by the regeneration con-
ditions. This system has also been tested in the oxidation of
bicyclo[3.2.0]hept-2-en-6-one with high selectivity (ees higher
than 90%).
It was also shown that the added FAD can be replaced by ri-
boflavin or FMN, which demonstrates that no significant ex-
change of reduced FAD with the protein-bound FAD occurs.
Scheme 20. The concept of using a fused BVMO (orange/top) and PTDH
(magenta/bottom) as biocatalyst. Such CRE/BVMO system supports effective
coenzyme regeneration. Some of the compounds that were prepared with
CRE/BVMOs are shown in the lower panel.[126, 130]
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This supports a catalytic role of the free flavin in the reduction
of the enzyme-bound cofactor. No evidence was found for
photoreduction of NADP+ . The major disadvantage of this
photochemical regeneration system is that the efficiency is sig-
nificant lower than that observed when employing conven-
tional regeneration methods. In more recent studies, it was
shown that the photochemical regeneration is limited by the
O2-dependent uncoupling of the regeneration systems from
the oxidation reaction and by the slow transfer between the
free and the BVMO-bound flavin.[135] To overcome the first
drawback, covalent attachment of the free flavin to the
enzyme surface via a linker can be considered, whereas for the
second limitation, smaller electron shuttle molecules or PAMO
variants with higher accessibility to the enzyme-bounded
flavin might be employed. Also the use of deazaflavins as
redox mediators might prevent the uncoupling reactions. In
fact, a recent study employing deazaflavins as mediators for
the photochemical regeneration of the P450 monooxygenase
BM3 from Bacillus megaterium in the hydroxylation of CH
bonds lead to an efficient process under aerobic conditions.[136]
Summary
During the past years, a highly complementary platform of
BVMOs has become available for diverse oxygenation reactions
such as desymmetrizations, regiodivergent transformations,
and (dynamic) kinetic resolutions. Individual representatives of
the available BVMO collection are able to operate on function-
ally and structurally diverse substrates (cycloketones, aromatic
ketones, linear ketones, and sulfides). It is possible to access
both enantiomers of a lactone, ester or sulfoxide in optically
pure form and good synthetic yields on a large number of
compounds. Preparative-scale biotransformations have been
realized by using purified enzymes or recombinant whole-cell
systems with both approaches offering certain pros and cons
depending on the given conversion. In many cases, the
enzyme-mediated Baeyer–Villiger oxygenation provides access
to optically pure lactones that are impossible to obtain by con-
ventional chemical methods. Although versatile, BVMOs are
also highly chemoselective. Except for representing valuable
biocatalytic tools, BVMOs have also been shown to be crucial
in several biological processes. Catabolic routes and the syn-
thesis of specific secondary metabolites have been shown to
fully depend on a particular BVMO activity. Of special interest
is the exploitation of BVMOs as prodrug targets. M. tuberculosis
infections have been often treated with a range of thiourea
and thioamide-containing prodrugs for decades. The antituber-
cular effect of these prodrugs is due to activation by a BVMO.
For performing effective BVMO-mediated catalysis several
technical issues need to be addressed. One prerequisite for opti-
mal BVMO activity is to supply the enzyme with sufficient reduc-
ing equivalents, typically by using NADPH. Several novel ap-
proaches for NADPH regeneration have been developed in
recent years. By using proper conditions, whole recombinant
cells provide an efficient format to perform catalysis as the intra-
cellular machinery is able to recycle NADP+ . The use of whole
cells has been integrated with the utilization of resins or a
second phase that enables the use of higher substrate concen-
trations and relatively easy work-up procedures. An alternative
approach for coenzyme recycling was achieved by fusing BVMOs
to a coenzyme-regenerating enzyme. These self-sufficient fusion
proteins were shown to be as effective in recycling NADPH, and
they retain full BVMO activity and selectivity. Another attractive
and novel approach for providing reducing equivalents has
been the finding that light can be used for this. By using several
additives in combination with light, BVMOs could be used as
biocatalysts without the need to recycle NADP+ .
Outlook
Enzyme-mediated Baeyer–Villiger oxygenations are still a de-
veloping field. With growing information on the structure of
the involved biocatalysts and their dynamic behavior upon
biotransformation, it gradually becomes possible to predict
and modify the catalytic performance of BVMOs. Still, crucial
aspects (enzyme stability, improved efficiency) have to be ad-
dressed and solved in a satisfactory manner, to make this
enzyme class even more appealing for future application on in-
dustrial scale. A variety of tools provided by molecular biology
have already been successfully applied to further improve the
capabilities of this enzyme group to be tailored to the needs
and expectations of modern synthesis. Except for discovery or
design of a proper BVMO, development of BVMO-based appli-
cations will also depend on efficient methodologies to support
optimal catalysis. A key issue is the coenzyme dependency of
BVMOs. Although the use of whole recombinant cells might be
a solution for a number of target reactions, it will not always
be applicable. Therefore, developing or improving novel ap-
proaches that involve the use of isolated enzymes is still an in-
teresting target for further research. Additional effort will be
required and might very well be expected in the immediate
future to ultimately establish enzyme mediated Baeyer–Villiger
oxidation as an attractive process in asymmetric organic syn-
thesis from lab-scale to industrial production.
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Scheme 21. Enzymatic Baeyer–Villiger oxidation of ketones employing light
as cofactor-regeneration system.[134] a) PAMO-P3/Tris-HCl, EDTA/NADPH/FAD.
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